Pacific Wealth Strategies Group Inc. Buys 641 Shares of Pfizer Inc. (NYSE:PFE)

Pacific Wealth Strategies Group Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,801 shares of the biopharmaceutical company’s stock after buying an additional 641 shares during the quarter. Pacific Wealth Strategies Group Inc.’s holdings in Pfizer were worth $465,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Castle Rock Wealth Management LLC raised its position in shares of Pfizer by 3.8% during the second quarter. Castle Rock Wealth Management LLC now owns 5,756 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 212 shares during the last quarter. Providence Wealth Advisors LLC raised its position in shares of Pfizer by 0.6% during the second quarter. Providence Wealth Advisors LLC now owns 40,404 shares of the biopharmaceutical company’s stock valued at $1,597,000 after buying an additional 230 shares during the last quarter. TD Capital Management LLC raised its position in shares of Pfizer by 12.0% during the second quarter. TD Capital Management LLC now owns 2,183 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 234 shares during the last quarter. Oarsman Capital Inc. raised its position in shares of Pfizer by 0.9% during the second quarter. Oarsman Capital Inc. now owns 26,320 shares of the biopharmaceutical company’s stock valued at $1,031,000 after buying an additional 234 shares during the last quarter. Finally, Bollard Group LLC raised its position in shares of Pfizer by 0.3% during the second quarter. Bollard Group LLC now owns 80,350 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 237 shares during the last quarter. 64.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PFE traded down $0.19 during mid-day trading on Thursday, hitting $50.89. 18,556,753 shares of the company traded hands, compared to its average volume of 30,943,912. The business has a 50 day moving average of $45.01 and a 200 day moving average of $43.27. The company has a market capitalization of $285.64 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.72. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $52.83. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 0.50.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 2nd. The biopharmaceutical company reported $1.34 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.26. The firm had revenue of $24.09 billion for the quarter, compared to analyst estimates of $22.82 billion. Pfizer had a return on equity of 31.66% and a net margin of 27.66%. Pfizer’s revenue for the quarter was up 134.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.72 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 4.2 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be given a $0.39 dividend. The ex-dividend date of this dividend is Thursday, November 4th. This represents a $1.56 dividend on an annualized basis and a yield of 3.07%. Pfizer’s dividend payout ratio is currently 46.43%.

In related news, insider John D. Young sold 150,000 shares of the company’s stock in a transaction that occurred on Thursday, November 11th. The stock was sold at an average price of $50.06, for a total value of $7,509,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.05% of the stock is owned by corporate insiders.

Several equities research analysts have recently issued reports on PFE shares. SVB Leerink reduced their price objective on shares of Pfizer from $50.00 to $48.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 3rd. Truist lifted their price objective on shares of Pfizer from $43.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday. Mizuho reaffirmed a “hold” rating and set a $43.00 price objective on shares of Pfizer in a research note on Sunday, October 3rd. Truist Securities boosted their target price on shares of Pfizer from $43.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Tuesday, October 12th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $49.00.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

See Also: What is a Stop Order?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.